Journal of Clinical Pathology · 2015 · 10 citations · 19 references
MedicineCancer BiologyOncologyBreast OncologyMetastasisMolecular OncologyBreast Cancer OncologyBreast Cancer RecurrenceEndocrine Tumor PrognosisHer2-positive Breast CancerMetastatic Breast CancerAndrogen Receptor ExpressionAndrogen ReceptorsBreast Cancer HistopathologyBreast Cancer Molecular SubtypesEstrogen Receptor ExpressionEstrogen Receptor StatusHormone Receptor - Positive Breast CancerMitotic Rate
BACKGROUND: The mechanisms underlying the favourable prognosis of androgen receptor (AR) expression in breast cancer are unknown. METHODS: The associations between the 21-gene recurrence score (RS), AR, grade, mitotic score, Ki-67 and estrogen receptor (ER) and progesterone receptor (PgR) expression were explored in sequential women with lymph node-negative, ER-positive and HER2-negative breast cancer. Statistical significance of this exploratory study was defined as p<0.10. RESULTS: Analysis comprised 70 women. Most tumours had high AR expression (97% had scores >3). Median RS was 15 (range 1-53). AR expression showed a minimally significant positive correlation with ER (R=0.37), but no correlation with Ki-67 (R=-0.18). In univariable analysis, AR (p=0.01), ER (p<0.001) and PgR (p<0.001) had significant negative associations with RS. Ki-67 (p=0.16), grade (p=0.40) and mitotic score (p=0.23) showed no association with RS. Multivariable analysis showed similar associations. CONCLUSIONS: AR is associated with lower RS, but not with Ki-67.
19
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik, Steven Shak, Gong Tang et al. · New England Journal of Medicine · 2004 · 6.4K citations · Full text
Medicine, Oncology, Breast Oncology +12
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Lisa A. Carey, Charles M. Perou, Chad Livasy et al. · JAMA · 2006 · 3.8K citations
Medicine, Biostatistics, Oncology +14
Jennet Harvey, Gary M. Clark, C. Kent Osborne et al. · Journal of Clinical Oncology · 1999 · 2.1K citations
Medicine, Endocrinology, Oncology +17